Form 8-K

8-K — BillionToOne, Inc.

Accession: 0002070849-26-000078

Filed: 2026-11-04

Period: 2026-11-04

CIK: 0002070849

SIC: 8071 (SERVICES-MEDICAL LABORATORIES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — blln-20261104.htm (Primary)

EX-99.1 (a991blln-earningspressrele.htm)

GRAPHIC (bllnlogo.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: blln-20261104.htm · Sequence: 1

blln-20261104

FALSE000207084900020708492026-05-062026-05-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2026

___________________________________

BillionToOne, Inc.

(Exact name of Registrant as specified in its charter)

___________________________________

Delaware

001-42934

81-1082020

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1035 O’Brien Drive

Menlo Park, CA 94025

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (650) 460-2551

(Former name or former address, if changed since last report)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol

Name of each exchange

on which registered

Class A common stock, par value $0.00001 per share

BLLN

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2026, BillionToOne, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language contained in such filing, unless otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit

Description

99.1

Press Release of BillionToOne, Inc. dated November 4, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BillionToOne, Inc.

Date:

November 4, 2026

By:

/s/ Ross Taylor

Name:

Ross Taylor

Title:

Chief Financial Officer

EX-99.1

Filename: a991blln-earningspressrele.htm · Sequence: 2

Document

BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance

MENLO PARK, CA, November 4, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2026 and raised guidance for full year 2026.

Financial Highlights:

●Total revenue of $123.0 million in the third quarter of 2026, compared to $83.5 million in the third quarter of 2025, an increase of 47%.

●Prenatal clinical testing revenue was $104.3 million in the third quarter of 2026, an increase of 41% from the third quarter of 2025.

●Oncology clinical testing revenue was $17.1 million in the third quarter of 2026, 96% higher than the $8.7 million reported in the third quarter of 2025.

●Gross profit margin was 71% in the third quarter of 2026, compared to 70% in the third quarter of 2025, a one percentage-point increase year-over-year.

●206,000 tests delivered in the third quarter of 2026, compared to 165,000 tests delivered in the third quarter of 2025, an increase of 25%.

●Income from operations of $11.0 million in the third quarter of 2026, compared to income from operations of $9.6 million in the third quarter of 2025.

●Free cash flow, defined as cash flow from operations minus capital expenditures, was $8.6 million in the third quarter of 2026.

●Raising 2026 full year revenue guidance to be in a range of $460 million to $470 million, which represents 51% to 54% growth over 2025.

●Expects to operate the business such that it will continue to generate profitability similar to current levels, even with significant continued investments.

Recent Operating Highlights:

●Today, we announced the upcoming launch of Northstar Clear, a tissue-free MRD test for patients with all solid tumors, which will be commercially available on December 15, 2026. Its pan-cancer, blood-only design makes it available on day one for all solid tumors, and initial data in colorectal cancer will show head-to-head performance against a tumor-informed assay.

●In October 2026, we announced peer-reviewed data published in The Journal of Liquid Biopsy from the first head-to-head comparison of Northstar Response with the most widely used tumor-informed assay in patients on active treatment for advanced cancer. The two assays agreed on the direction of ctDNA change in 94% of sequential pairs (67 of 71), and in all four divergent cases clinical records supported Northstar Response’s findings.

●In August 2026, we announced peer-reviewed data published in The Green Journal (Obstetrics & Gynecology) validating Unity Fetal Risk Screen as a first-line prenatal screen. The study is the first and largest prospective study of Unity Fetal Risk Screen in its intended-use population and was conducted in collaboration with nine U.S. institutions, demonstrating 94.4% sensitivity and 99.5% specificity.

“Our third quarter was another period of strong execution,” said Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne. “We delivered rapid growth with continued GAAP profitability, and more clinicians are

choosing our tests in both prenatal and oncology. This quarter we also strengthened the clinical evidence behind our platform. Published data validated Unity Fetal Risk Screen as a first-line prenatal screen, and Northstar Response delivered strong results in the first head-to-head study of its kind. I am also pleased to announce that next month, we plan to launch Northstar Clear, our MRD test. Overall, we are proud of our performance so far in 2026 and believe we are still in the early chapters of what our platform can achieve.”

Three Months Ended

September 30, (Unaudited) Nine Months Ended

September 30, (Unaudited)

2026 2025 % 2026 2025 %

Revenue ($ in millions)

Prenatal $ 104.3 $ 74.1 41 % $ 295.1 $ 191.0 54 %

Oncology $ 17.1 $ 8.7 96 % $ 41.4 $ 15.8 162 %

Clinical trial support and other services $ 1.6 $ 0.8 115 % $ 4.3 $ 2.2 92 %

Total Revenue $ 123.0 $ 83.5 47 % $ 340.8 $ 209.1 63 %

Note: Numbers may not add due to rounding

Three Months Ended

September 30, (Unaudited) Nine Months Ended

September 30, (Unaudited)

2026 2025 % 2026 2025 %

Total tests accessioned 207,000 163,000 27 % 593,000 448,000 32 %

Total tests delivered 206,000 165,000 25 % 590,000 441,000 34 %

Overall ASP $ 589 $ 501 18 % $ 571 $ 469 22 %

Third Quarter 2026 Financial Results

Total revenue was $123.0 million in the third quarter of 2026 compared to $83.5 million in the third quarter of 2025, an increase of 47%. The increase in total revenue was driven by a 25% increase in the number of total tests delivered and an 18% increase in Overall ASP. Both prenatal and oncology delivered strong test volume growth year-over-year.

Gross profit was $87.1 million in the third quarter of 2026, compared to $58.4 million in the third quarter of 2025, representing a gross margin of 71% in the third quarter of 2026 and 70% in the third quarter of 2025. An increase in Overall ASP drove the improvement in gross profit margin compared to the third quarter of 2025. Overall cost-per-test increased slightly in the third quarter of 2026 compared to last year. The increase was driven by the faster growth of our oncology products, which have higher costs per test, and a slight increase in our prenatal cost per test, partially offset by improvements in cost-per-test for both of our oncology products.

Total operating expenses were $76.1 million in the third quarter of 2026, compared to $48.8 million in the third quarter of 2025, an increase of 56%.

Income from operations was $11.0 million in the third quarter of 2026, compared to income from operations of $9.6 million in the third quarter of 2025. Operating margin was 9% in the third quarter of 2026.

Net income in the third quarter of 2026 was $17.4 million, or $0.32 per diluted share, compared to net income of $1.5 million, or $0.10 per diluted share, in the third quarter of 2025.

Financial Outlook

BillionToOne now expects full year 2026 total revenue of $460.0 million to $470.0 million, representing growth of 51% to 54% compared to full year 2025. This compares to the company's previous guidance of $450.0 million to $465.0 million.

BillionToOne also expects to operate the business such that it will continue to generate profitability similar to current levels, even with significant continued investments.

Webcast and Conference Call Information

BillionToOne will host a conference call today, November 4, 2026, at 1:30pm Pacific Time / 4:30pm Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event for interested listeners can be accessed at

https://investors.billiontoone.com/.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding revenue, income and other financial information for the full year of 2026. These statements are based on management’s current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, some of which are beyond BillionToOne’s control. These and additional risks and uncertainties that could affect BillionToOne’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These risks and uncertainties include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in BillionToOne’s most recently filed quarterly report on Form 10-Q, the annual report on Form 10-K and other filings BillionToOne makes with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to BillionToOne as of the date hereof, and BillionToOne disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing BillionToOne’s views as of any date subsequent to the date of this press release.

Non-GAAP financial measures

We use certain non-GAAP financial measures to supplement our unaudited financial results, which are presented in accordance with GAAP. These non-GAAP financial measures include EBITDA, adjusted EBITDA and free cash flow. By excluding the impact of certain items that we believe do not directly reflect our underlying operations, we are of the opinion that EBITDA, adjusted EBITDA and free cash flow provide meaningful supplemental information regarding our performance. Accordingly, we believe these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and forecasting. These metrics also provide investors and other users of our financial information with additional tools to compare business performance across companies and periods, while eliminating the effects of items that may vary for different companies for reasons unrelated to core operating performance. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables. A reconciliation of the forecasted range for adjusted EBITDA for the full year 2026 is not included in this release due to the number of variables in the projected range and because we are currently unable to quantify accurately certain amounts that would be required to be included in the U.S. GAAP measure or the individual adjustments for such reconciliation.

EBITDA

We define EBITDA as net income (loss) adjusted for income taxes, interest income, interest expense, and depreciation and amortization expense.

Adjusted EBITDA

We define Adjusted EBITDA as net income (loss) adjusted for income taxes, interest income, interest expense, depreciation and amortization expense, and certain other items which include significant non-cash items and events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations, which include: stock-based compensation expense; change in fair value of term loan; and change in fair value of warrant liabilities.

Free Cash Flow

We define Free Cash Flow as net cash provided by operating activities adjusted for purchases of property and equipment.

BillionToOne, Inc.

Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share amounts, unaudited)

Three Months Ended

September 30, Nine Months Ended

September 30,

2026 2025 2026 2025

Revenue $ 122,981 $ 83,523 $ 340,817 $ 209,059

Cost of revenue 35,836 25,107 97,469 69,205

Gross profit 87,145 58,416 243,348 139,854

Operating expenses:

Research and development 20,216 12,953 52,223 35,134

Selling, general and administrative 55,906 35,830 156,765 99,029

Total operating expenses 76,122 48,783 208,988 134,163

Income from operations 11,023 9,633 34,360 5,691

Other income (expense):

Interest income 4,912 1,535 14,251 4,492

Interest expense (6) (20) (24) (92)

Change in fair value of term loan 1,482 (3,936) (5,747) (7,038)

Other income (expense), net (19) (1,630) 579 (1,591)

Total other income (expense) 6,369 (4,051) 9,059 (4,229)

Income before provision for income taxes 17,392 5,582 43,419 1,462

Provision for income taxes 1 (129) 4 (15)

Net income $ 17,391 $ 5,711 $ 43,415 $ 1,477

Less: Net income attributable to participating securities - (4,204) - (1,089)

Net income attributable to common stockholders $ 17,391 $ 1,507 $ 43,415 $ 388

Other comprehensive income, net of taxes:

Change in fair value of term loan attributable to instrument‑specific credit risk $ (1,069) $ - $ (1,069) $ -

Other comprehensive loss, net of taxes (1,069) - (1,069) -

Comprehensive income, net of taxes $ 16,322 $ 5,711 $ 42,346 $ 1,477

Net income per share, basic and diluted:

Net income per share, basic $ 0.37 $ 0.14 $ 0.93 $ 0.04

Net income per share, diluted $ 0.32 $ 0.10 $ 0.81 $ 0.03

Weighted-average shares used in calculating net income per share, basic and diluted:

Weighted-average shares used in calculating net income per share, basic 47,271,383 10,429,583 46,540,721 10,376,253

Weighted-average shares used in calculating net income per share, diluted 53,732,158 15,571,949 53,743,737 15,117,365

BillionToOne, Inc.

Balance Sheets

(in thousands, except share amounts, unaudited)

September 30, 2026 December 31, 2025

Assets

Current assets:

Cash and cash equivalents $ 561,512 $ 495,975

Accounts receivable 88,283 41,617

Inventories 21,891 17,545

Prepaid expenses and other current assets 10,407 5,421

Total current assets 682,093 560,558

Property and equipment, net

26,784 20,361

Operating lease right-of-use assets, net

46,300 46,742

Other non-current assets

5,313 4,993

Total assets $ 760,490 $ 632,654

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable $ 10,232 $ 7,184

Accrued expenses and other current liabilities 15,018 7,247

Accrued commissions 3,465 3,912

Accrued compensation and employee benefits 22,869 12,551

Common stock warrant liability — 9,282

Deferred revenue, current 1,884 2,188

Operating lease liabilities, current 6,784 5,079

Financing lease liabilities, current 385 519

Total current liabilities 60,637 47,962

Operating lease liabilities, non-current 44,222 45,723

Financing lease liabilities, non-current 75 348

Deferred revenue, non-current 28 1,290

Long-term debt 88,982 57,226

Total liabilities 193,944 152,549

Stockholders’ equity:

Class A common stock, $0.00001 par value, 800,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 43,128,349 and 41,252,105 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

— —

Class B common stock, $0.00001 par value; 10,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 4,502,650 and 4,552,650 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively

— —

Additional paid-in capital

800,739 756,644

Accumulated other comprehensive loss (2,861) (1,792)

Accumulated deficit

(231,332) (274,747)

Total stockholders’ equity

566,546 480,105

Total liabilities and stockholders’ equity

$ 760,490 $ 632,654

BillionToOne, Inc.

Statements of Cash Flows

(in thousands, unaudited)

Nine Months Ended September 30,

2026 2025

Cash flows from operating activities:

Net income $ 43,415 $ 1,477

Adjustments to reconcile net income to net cash provided by operating activities:

Stock-based compensation

24,430 9,581

Depreciation and amortization

5,540 5,232

Amortization of operating right-of-use assets

4,432 3,715

Loss on disposal of fixed assets

82 7

Change in fair value of common stock warrant liability

(62) 1,409

Change in fair value of redeemable convertible preferred stock warrant liability

- 176

Change in fair value of term loan

687 3,505

Changes in operating assets and liabilities:

Accounts receivable

(46,666) (9,937)

Inventories

(4,346) (8,656)

Prepaid expenses and other current assets

(4,903) (1,727)

Other non-current assets

(320) (62)

Accounts payable

4,025 3,047

Accrued expenses and other current liabilities

7,871 3,972

Accrued commissions

(447) 166

Accrued compensation and employee benefits

8,727 5,268

Deferred revenue

(1,566) (123)

Operating lease liabilities

(3,786) (3,247)

Net cash provided by operating activities 37,113 13,803

Cash flows from investing activities:

Purchases of property and equipment

(12,466) (7,344)

Net cash used in investing activities (12,466) (7,344)

BillionToOne, Inc.

Statements of Cash Flows

(in thousands, unaudited)

Nine Months Ended September 30,

2026 2025

Cash flows from financing activities:

Proceeds from issuance of debt 30,000 -

Principal payments on finance lease liabilities

(407) (1,449)

Payment of deferred offering costs

(504) (2,516)

Proceeds from exercise of stock options

12,236 1,181

Taxes paid related to net share settlement of equity awards

(435) -

Net cash provided by (used in) financing activities 40,890 (2,784)

Net increase in cash and cash equivalents 65,537 3,675

Cash and cash equivalents at beginning of period

495,975 191,477

Cash and cash equivalents at end of period

$ 561,512 $ 195,152

Supplemental cash flow disclosure:

Cash payments for interest

$ 5,084 $ 3,626

Cash paid for income taxes

$ 393 $ 460

Supplemental cash flow information and non-cash investing and financing activities:

Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities

$ 1,970 $ 500

Deferred offering costs in accounts payable and accrued expenses and other current liabilities

$ - $ 1,144

Right-of-use assets obtained in exchange for new operating lease liabilities

$ 4,034 $ -

Cash paid for amounts included in the measurement of operating lease liabilities

$ 7,135 $ 6,594

Net exercise of Class A common stock warrants

$ 9,220 $ -

Operating cash flows from financing leases (interest paid)

$ 24 $ 89

Exercise of stock options for which cash had not been received $ 86 $ -

BillionToOne, Inc.

Reconciliation of Net Income (Loss) to EBITDA

(in thousands, unaudited)

Three Months Ended

September 30, Nine Months Ended

September 30,

2026 2025 2026 2025

Net income $ 17,391 $ 5,711 $ 43,415 $ 1,477

Provision for income taxes 1 (129) 4 (15)

Interest (income) (4,912) (1,535) (14,251) (4,492)

Interest expense 6 20 24 92

Depreciation and amortization 1,973 1,692 5,540 5,232

EBITDA $ 14,459 $ 5,759 $ 34,732 $ 2,294

Reconciliation of Net Income (Loss) to Adjusted EBITDA

(in thousands, unaudited)

Three Months Ended

September 30, Nine Months Ended

September 30,

2026 2025 2026 2025

Net income $ 17,391 $ 5,711 $ 43,415 $ 1,477

Provision for income taxes 1 (129) 4 (15)

Interest (income) (4,912) (1,535) (14,251) (4,492)

Interest expense 6 20 24 92

Depreciation and amortization 1,973 1,692 5,540 5,232

Stock-based compensation expense 9,703 4,475 24,430 9,581

Change in fair value of term loan (1,482) 3,936 5,747 7,038

Change in fair value of warrant liabilities - 1,627 (62) 1,585

Adjusted EBITDA $ 22,680 $ 15,797 $ 64,847 $ 20,498

Reconciliation of Free Cash Flow to Net Cash Provided by Operating Activities

(in thousands, unaudited)

Three Months Ended

September 30, Nine Months Ended

September 30,

2026 2025 2026 2025

Net cash provided by operating activities $ 12,547 $ 9,996 $ 37,113 $ 13,803

Purchases of property and equipment (3,946) (2,123) (12,466) (7,344)

Free cash flow $ 8,601 $ 7,873 $ 24,647 $ 6,459

Investor Contact

ir@billiontoone.com

Media Contact

billiontoone@moxiegrouppr.com

GRAPHIC

Filename: bllnlogo.jpg · Sequence: 6

Binary file (7830 bytes)

Download bllnlogo.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

May 06, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Nov. 04, 2026

Registrant Name

BillionToOne, Inc.

Entity Incorporation, State or Country Code

Entity File Number

001-42934

Entity Tax Identification Number

81-1082020

Entity Address, Address Line One

1035 O’Brien Drive

Entity Address, City or Town

Menlo Park

Entity Address, State or Province

Entity Address, Postal Zip Code

94025

City Area Code

650

Local Phone Number

460-2551

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A common stock, par value $0.00001 per share

Trading Symbol

BLLN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Entity Ex Transition Period

false

Amendment Flag

false

Central Index Key

0002070849

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration